Vanda Pharmaceuticals Inc.

Stocks

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-06-16 pm EDT			5-day change	1st Jan Change
5.730 ^USD	-2.55%		-6.37%	-35.03%

May. 07	Vanda Pharmaceuticals Inc., Q1 2026 Earnings Call, May 06, 2026
May. 06	Vanda Pharmaceuticals Inc. Raises Revenue Guidance for the Full-Year 2026	CI

Vanda Pharmaceuticals Inc. Raises Revenue Guidance for the Full-Year 2026

Published on 05/06/2026 at 04:01 pm EDT

S&P Capital IQ

VANDA PHARMACEUTICALS INC.

-2.55%

Vanda Pharmaceuticals Inc. raised revenue guidance for the full-year 2026. For the period, the company expects Total revenues to be in the range of $240 million to $290 million as compared to previous guidance of $230 million to $260 million.

Latest news about Vanda Pharmaceuticals Inc.

May. 07	Vanda Pharmaceuticals Inc., Q1 2026 Earnings Call, May 06, 2026
May. 06	Vanda Pharmaceuticals Inc. Raises Revenue Guidance for the Full-Year 2026	CI
May. 06	Vanda Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 04	Sector Update: Health Care Stocks Softer Late Afternoon	MT
May. 04	Vanda Pharmaceuticals Launches Motion Sickness Drug Nereus in US	MT
May. 04	Vanda Pharmaceuticals announces U.S. commercial availability of Nereus(TM) (tradipitant), the first new pharmacologic treatment for people with motion sickness in more than 40 years	RE
May. 01	Vanda Pharmaceuticals US availability of Nereus for people with motion sickness	RE
May. 01	Vanda Pharmaceuticals Inc. Announces Commercial Availability of Nereus (Tradipitant) for Motion Sickness Prevention in the United States	CI
Apr. 22	Vanda Pharmaceuticals Inc. Appoints Charles Duncan to Its Board of Directors, Effective April 22, 2026	CI
Apr. 13	Geron Corporation Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary	CI
Apr. 09	Vanda Asks FDA to Withdraw Proposal Extending Drug Review Timelines	MT
Apr. 08	Vanda Pharmaceuticals Starts Study of Nereus to Address GLP-1 Side Effects	MT
Apr. 08	Vanda Pharmaceuticals announces initiation of the Thetis study, a clinical trial of Nereus(TM) for the prevention of vomiting induced by GLP-1 receptor agonists	RE
Apr. 08	Vanda Pharmaceuticals Inc. Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS? for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists	CI
Apr. 02	Vanda Pharmaceuticals Inc. Announces Resignation of Timothy Williams as Senior Vice President, General Counsel and Secretary, Effective April 10, 2026	CI

Chart Vanda Pharmaceuticals Inc.

Duration

Period

VNDA: Dynamic Chart

Company Profile

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company, which is focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company's commercial portfolio consist of four products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome, PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS) including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease , and NEREUS for the prevention of vomiting induced by motion. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.

Employees

533

Sector

Biotechnology & Medical Research

More about the company